A Randomized Double-Blind Study Using CaNa₂EDTA, a Phospholipase A₂ Inhibitor, in the Management of Human Acute Pancreatitis

H. T. Tykkau Laboratory of Immunology, Helsinki University Central Hospital; Maria Hospital of Helsinki City; and Dept. of Public Health Science, Helsinki University, Helsinki, Finland

E. J. Vaittinen Laboratory of Immunology, Helsinki University Central Hospital; Maria Hospital of Helsinki City; and Dept. of Public Health Science, Helsinki University, Helsinki, Finland

K. L. Mahlberg Laboratory of Immunology, Helsinki University Central Hospital; Maria Hospital of Helsinki City; and Dept. of Public Health Science, Helsinki University, Helsinki, Finland

J. E. Railo Laboratory of Immunology, Helsinki University Central Hospital; Maria Hospital of Helsinki City; and Dept. of Public Health Science, Helsinki University, Helsinki, Finland

P. J. Pantzar Laboratory of Immunology, Helsinki University Central Hospital; Maria Hospital of Helsinki City; and Dept. of Public Health Science, Helsinki University, Helsinki, Finland

S. Sarna Laboratory of Immunology, Helsinki University Central Hospital; Maria Hospital of Helsinki City; and Dept. of Public Health Science, Helsinki University, Helsinki, Finland

T. Tallberg Laboratory of Immunology, Helsinki University Central Hospital; Maria Hospital of Helsinki City; and Dept. of Public Health Science, Helsinki University, Helsinki, Finland

show all

Abstract

In a randomized double-blind study the effect of CaNa₂EDTA, a phospholipase A₂ inhibitor, was tested as a treatment for acute pancreatitis. CaNa₂EDTA was infused intravenously during the first 2 days after admission to hospital, in addition to normal conservative treatment. CaNa₂EDTA decreased the serum phospholipase A₂ activity and appeared to promote recovery from the illness. To what extent the inhibition of serum phospholipase activity may prevent the progress of severe haemorrhagic pancreatitis or diminish mortality and morbidity in acute pancreatitis should be investigated in further studies.

Key Words:

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

A Randomized Double-Blind Study Using CaNa₂EDTA, a Phospholipase A₂ Inhibitor, in the Management of Human Acute Pancreatitis

Information for

Open access

Opportunities

Help and information

A Randomized Double-Blind Study Using CaNa2EDTA, a Phospholipase A2 Inhibitor, in the Management of Human Acute Pancreatitis

Abstract

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature

A Randomized Double-Blind Study Using CaNa₂EDTA, a Phospholipase A₂ Inhibitor, in the Management of Human Acute Pancreatitis